3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Classical hematology
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thrombosis
2
Pancreatic Neoplasms
2
Thromboembolism
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Ovarian Neoplasms
1
Obesity
1
Multiple Myeloma
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Embolism and Thrombosis
1
Embolism
1
Duodenal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Vitamin D
2
Tirzepatide
2
Metformin
2
licogliflozin
1
indole-3-carbinol
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
Tablets
1
Specimen Handling
1
Resistance Training
1
Progestins
1
Pregabalin
1
Orlistat
1
Organizational Objectives
1
Omeprazole
1
Observation
1
Naltrexone
1
Ketorolac
1
Exergaming
1
Exercise
1
Exenatide
1
Diet, Plant-Based
1
Dexmedetomidine
1
Dalteparin
1
Counseling
1
Cholecalciferol
1
Calcium Citrate
1
Calcium Carbonate
1
Calcitriol
1
CKD732
1
Bupropion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Obesity
×
Dalteparin
×
Clear all
NCT03297359
2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2
Terminated
92 enrolled